Sun Pharma Advanced Research Company Limited (BOM:532872)

Market Cap	51.78B
Revenue (ttm)	717.70M
Net Income (ttm)	-3.43B
Shares Out	n/a
EPS (ttm)	-10.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,609
Average Volume	205,628
Open	161.40
Previous Close	159.00
Day's Range	158.05 - 161.40
52-Week Range	109.20 - 257.70
Beta	n/a
RSI	50.40
Earnings Date	Aug 4, 2025

About BOM:532872

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 409
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532872

Financial Performance

In 2024, BOM:532872's revenue was 717.70 million, a decrease of -5.00% compared to the previous year's 755.45 million. Losses were -3.43 billion, -11.55% less than in 2023.